Abstracts tagged "anti-TNF therapy"

Abstract Number: 558 • 2012 ACR/ARHP Annual Meeting
Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Joachim Sieper¹, Alan J. Kivitz², A.M. Van Tubergen³, Atul A. Deodhar⁴, Geoffroy Coteur⁵, Franz Woltering⁶ and Robert B. M. Landewé⁷, ¹Medical Department I, Rheumatology, Charité University Medicine, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the…
Abstract Number: 363 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Pernille Bøyesen², Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Ditte Dencker¹, Hanne M. Lindegaard³, Uta Engling Poulsen¹, Annette Hansen⁴, Vibeke Stevenius Ringsdal¹, Annette Schlemmer⁵, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Torben Grube Christensen¹, Randi Pelck¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹, Ole Majgaard¹ and Merete L. Hetland⁶, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ³Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁴Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: : Despite treatment with tumour necrosis factor inhibitors (TNFi) some rheumatoid arthritis (RA) patients progress radiographically in randomised controlled trials and observational cohorts (1).…
Abstract Number: 1848 • 2012 ACR/ARHP Annual Meeting
Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database
Andrew S. Koenig¹, Jack Mardekian² and Sameer Kotak³, ¹Specialty Care, Pfizer Inc, Collegeville, PA, ²Pfizer Inc, New York, NY, ³Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Joint replacement surgery patterns continue to change in patients with rheumatoid arthritis (RA), possibly reflecting the widespread adoption of disease modifying antirheumatic drugs, earlier…
Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Anthony Marotta¹, A. W van Kuijk², Walter P. Maksymowych³ and Paul Peter Tak⁴, ¹Augurex Life Sciences Corp, North Vancouver, BC, Canada, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…
Abstract Number: 173 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Ieda Laurindo¹, Ana C. M. Ribeiro¹, Julio C. B. Moraes², Carla G.S. Saad¹, Karina Rossi Bonfiglioli³, Fernando H.C. Souza³, Ana L. G. Calich¹, Mariana G. Waisberg¹, Lissiane K. N. Guedes³ and Eloisa Bonfa¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Background: Current recommendations for latent tuberculosis infection (LTB) screening and treatment in patients eligible for anti-TNF agents are not well established in endemic regions.…
Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Elisabeth Lie¹, Karen M. Fagerli², Knut Mikkelsen³, Åse S. Lexberg⁴, Erik Rødevand⁵, Till Uhlig¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, Oslo, Norway, ³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…
Abstract Number: 1330 • 2012 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
Marianne van den Broek¹, L. Heimans², S. le Cessie³, B. Siegerink³, H.K Ronday⁴, K.H. Han⁵, P.J.S.M. Kerstens⁶, T.W.J. Huizinga², W.F. Lems⁷ and C.F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University medical center, Amsterdam, Netherlands
High BMI is associated with decreased response to initial combination therapy in recent onset RA patients Background/Purpose: A diminished response to combination treatment with a fixed…
Abstract Number: 543 • 2012 ACR/ARHP Annual Meeting
Wnt Pathway Inhibitors in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNF Therapy
Agnes Szentpetery¹, Harjit P. Bhattoa², Peter Antal-Szalmas², Zoltan Szekanecz³ and Oliver M. FitzGerald⁴, ¹Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Laboratory Medicine, Department of Laboratory Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary, ³Rheumatology, Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Both rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterised by bone erosion but aberrant bone formation is also a feature in PsA. Wnt…
Abstract Number: 132 • 2012 ACR/ARHP Annual Meeting
FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs
Koichi Okamura¹, Yukio Yonemoto², Tetsuya Kaneko³, Kimihiko Takeuchi⁴, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan, ⁴Department of Rheumatology, Isesaki Fukushima Hospital, Isesaki, Gunma, Japan
Background/Purpose: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). The development of molecular…
Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Alain Saraux¹, Jacques Benichou², Chantal Deslandre³, Loic Guillevin⁴, Latifa Idbrik⁵, Jean Sibilia⁶, Marc Soudan⁵, Daniel Wendling⁷ and Francis Guillemin⁸, ¹Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, ²INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, EA4438 Laboratoire Physiopathologie des Arthrites, Rouen, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ⁵Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, ⁶Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ⁷Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁸Hopitaux de Brabois, Nancy, France
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…
Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Roy Fleischmann¹, Steven De Bruyn², Christian Duby², Katrien Verschueren³, Judith Baumeister⁴, Laura Sargentini-Maier⁵, Cedric Ververken⁶ and Josefin-Beate Holz⁷, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ³Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ⁴Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁵Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁶Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁷Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…
Abstract Number: 546 • 2012 ACR/ARHP Annual Meeting
The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients
Chamaida Plasencia¹, Dora Pascual-Salcedo², Sara Garcia-Carazo³, Gema Bonilla⁴, Leticia Lojo⁵, Laura Nuño⁶, Alejandro Villalba⁷, Diana Peiteado⁷, Concepcion Castillo-Gallego⁷, Florencia Arribas², Daniel Nagore⁸, E. Martin-Mola⁹ and Alejandro Balsa⁴, ¹Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, ²Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ³La PAZ University Hospital, RHEUMATOLOGY UNIT, Spain, Spain, ⁴Rheumatology, Hospital La Paz, Madrid, Spain, ⁵Rheumatology, Hospital Universitario La Paz, Spain, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁸Proteomika S.L., ⁹Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Spondyloarthropathies (SpAs) encompass a heterogeneous group of diseases that primarily affect the axial skeleton and entheses. Although anti-TNF drugs have proven to be effective…
Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Shintaro Hirata¹, Douglas J. Haney², Guy Cavet², Rebecca Bolce², Wanying Li², Nadine Defranoux², David Chernoff², Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA). A validated multi-biomarker disease activity algorithm (MBDA) blood…
Abstract Number: 1818 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Fabrizio Cantini¹, Ennio Lubrano², Alessandro Mathieu³, Antonio Marchesoni⁴, Carlo Salvarani⁵, Raffaele Scarpa⁶ and Antonio Spadaro⁷, ¹U.O.C. Reumatologia, Prato Hospital, Prato, Italy, ²Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶c/o Medical University, Via Pansini 5, Naples, Italy, ⁷Cattedra di Reumatologia, Univeristà La Sapienza di Roma, Roma, Italy
Background/Purpose: Anti-TNFα drugs are associated with an increased risk of tuberculosis (TB) and several recommendation sets for latent tubercular infection (LTBI) detection and TB reactivation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].